Top View
- Supplementary File 1
- Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
- FDA-Approved Drugs Under Investigation in Multiple Myeloma for Actionable Targets
- 2018 at a Glance: Recently Approved Therapies in Oncology
- Oncogenic and Sorafenib-Sensitive ARAF Mutations in Lung Adenocarcinoma
- Treatment of Melanoma and Breast Cancer
- New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
- Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma
- Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell L
- 1 Title: the BRAF and MEK Inhibitors Dabrafenib and Trametinib
- Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K- Mutated Melanoma Federica Catal
- Phosphoprotein Patterns Predict Trametinib Responsiveness and Optimal Trametinib Sensitisation Strategies in Melanoma
- Efficacy of Dabrafenib Plus Trametinib Combination in Patients
- Trametinib (Mekinist®), Dabrafenib (Tafinlar®) EOCCO POLICY
- BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma LISA WALTER and LUCIE HEINZERLING
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- 1. Metastatic HER2 Positive HR POSITIVE BREAST
- Drug Updates Medina FINAL.Pptx
- DCC-2618, a Broad-Spectrum Inhibitor of KIT and PDGFRA Mutants, Synergizes with Inhibitors of the MAPK Pathway Anu Gupta1, Cynthia B
- Dual-Specificity Protein Phosphatase DUSP4 Regulates Response to MEK
- Overcoming Resistance to BRAFV600E Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network Alterations
- FOI 281-1718 Document 2
- The MEK Inhibitors Enhance the Efficacy of Sorafenib Against Hepatocellular Carcinoma Cells Through Reducing P-ERK Rebound
- Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- MEKINIST (Trametinib) Tablets Are Supplied As 0.5 Mg and 2 Mg Tablets for Oral Administration
- Dabrafenib) Capsules, for Oral Use Serious Skin Toxicity: Monitor for Skin Toxicities
- Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis In
- Targeted Therapies in Melanoma
- MAP3K1 and MAP2K4 Mutations Are Associated with Sensitivity to MEK Inhibitors in Multiple Cancer Models
- Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations Or Fusions: Results from NCI-MATCH (EAY131) Douglas B
- An Attempt to Quantitate “Value” in Medical Oncologic Therapy
- Madison M. Rose, TC Beadnell, LA Pike, and RE Schweppe University of Colorado Anschutz Medical Campus
- Oncology Agents Policy #: Rx.01.67
- Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib And
- Combining Tkis in Melanoma
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation
- Trametinib) Tablets, for Oral Use Discontinue MEKINIST
- Response to MEK Inhibition with Trametinib and 5 Every 21 Days)
- Trastuzumab (HERCEPTIN) Monograph
- Trametinib with and Without Pazopanib Has Potent Preclinical Activity in Thyroid Cancer
- ST No Specified Mutations
- Clinical Trials Appendix Q1 2019 Results Update
- Mekinist, INN-Trametinib
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Response to MEK Inhibition with Trametinib and Tyrosine
- Efficacy and Biomarker Analysis of Adavosertib in Differentiated
- Current Development Status of MEK Inhibitors
- Increased MAPK Reactivation in Early Resistance to Dabrafenib/Trametinib Combination Therapy of BRAF-Mutant Metastatic Melanoma
- 409 Oncology Drugs
- Trametinib-Based Treatment of Pediatric CNS Tumors: Ver Thepediatric Last Brain Decade, Tumors Has Next Led Generation to the Sequencing Identi Of
- NF1 Clinical Pipeline: Active Interventional Drug Therapies
- Cell Line Panel Profiling Reveals That MEK Inhibitors
- HOPA News Volume 10, Issue 3, 2013
- Vemurafenib and Trametinib Reduce Expression of CTGF and IL-8 In
- Current Insights Into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
- Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Victoria L
- USMAJDT Protocol
- Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer